{"product_id":"calcitonin-gene-related-peptide-cgrp-8-37-rat","title":"Calcitonin Gene Related Peptide (CGRP) (8-37), Rat","description":"\u003cdiv style=\"max-width:1400px; margin:0 auto; padding:40px 20px; font-family:'Open Sans',sans-serif; font-weight:300; background:#fff; color:#333; font-size:0.95rem; box-sizing:border-box;\"\u003e\n  \u003cdiv style=\"display:flex; flex-direction:column; gap:20px;\"\u003e\n\u003ch2 style=\"margin:0; font-weight:600;\"\u003eCalcitonin Gene Related Peptide (CGRP) (8-37), Rat – Catalog #B2026702\u003c\/h2\u003e\n\u003cp\u003eCalcitonin Gene Related Peptide (CGRP) (8-37), Rat (Catalog #B2026702) is a rat-derived CGRP fragment supplied as 0.5 mg of lyophilized powder. The (8-37) form—missing the N-terminal 1-7 residues—acts as a competitive antagonist at the CGRP receptor, making it invaluable for studying CGRP-mediated signaling, pain pathways, and vascular responses. This fragment is distinct from full-length CGRP and has become a key tool in migraine and pain research.\u003c\/p\u003e\n\u003cdiv style=\"overflow-x:auto; max-width:100%; margin-bottom:20px;\"\u003e\n\u003ctable style=\"width:100%; max-width:640px; border-collapse:collapse;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eCatalog number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eB2026702\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eLot number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eExpiration Date:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eAmount:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e0.5 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eMolecular Weight or Concentration:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSupplied as:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eLyophilized Powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSource:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eRat (synthetic)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eApplications:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eCGRP receptor antagonism studies, migraine pain research, vascular dysfunction research, neuropeptide signaling, CGRP-targeted drug validation, pain pathway investigation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eStorage:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e−20°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eCGRP, Calcitonin Gene-Related Peptide, CGRP (8-37), CGRP antagonist, Rat CGRP, Neuropeptide, CGRP fragment, CGRP receptor antagonist, Migraine research, Pain signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eGrade:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBiotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity \u0026gt;18 MΩ-cm) and are filtered through 0.22 um.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eScientific Overview\u003c\/h3\u003e\n\u003cp\u003eCGRP is a 37-amino-acid neuropeptide derived from alternative splicing of the calcitonin gene. It exists in two forms: α-CGRP (more prevalent in sensory neurons) and β-CGRP (primarily in endocrine cells). CGRP acts via a G-protein–coupled receptor present in the central and peripheral nervous systems, on blood vessel endothelium, and in immune cells. CGRP is a potent vasodilator and has been implicated in migraine pathophysiology, inflammatory pain, and cardiovascular regulation.\u003c\/p\u003e\n\u003cp\u003eThe CGRP (8-37) fragment is an antagonist that competitively blocks CGRP receptor binding. By removing the N-terminal 1-7 amino acids required for full receptor agonism, this fragment provides a research tool to study CGRP's pharmacological mechanisms and to validate CGRP-targeted therapies for migraine and pain conditions.\u003c\/p\u003e\n\u003cp\u003eKey applications include:\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eCGRP receptor antagonism and competitive inhibition studies\u003c\/li\u003e\n\u003cli\u003eInvestigation of CGRP's role in migraine and headache pathophysiology\u003c\/li\u003e\n\u003cli\u003ePain signaling and neuropeptide research\u003c\/li\u003e\n\u003cli\u003eVascular dysfunction and vasodilation mechanism studies\u003c\/li\u003e\n\u003cli\u003eValidation of CGRP-targeting monoclonal antibodies and small-molecule drugs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eUsage \u0026amp; Handling Guidance\u003c\/h3\u003e\n\u003cp\u003eStore lyophilized powder at −20°C. Reconstitute in sterile, distilled water or assay buffer immediately before use. Prepare working aliquots to minimize freeze–thaw stress on the peptide.\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Dissolve in sterile PBS, Tris buffer, or your preferred assay medium. Concentration is experiment-dependent. Request the COA\/TDS for specific lot details.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntagonism assay:\u003c\/strong\u003e Co-incubate CGRP (8-37) with full-length CGRP in receptor binding or signaling assays to assess competitive antagonism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Peptides may aggregate or oxidize in solution. Use fresh preparations when possible, or store short-term at 2–8°C.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhat You Get\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e0.5 mg of rat CGRP (8-37), supplied as lyophilized powder\u003c\/li\u003e\n\u003cli\u003eA well-characterized CGRP receptor antagonist\u003c\/li\u003e\n\u003cli\u003eHigh-purity peptide for receptor studies and competitive inhibition assays\u003c\/li\u003e\n\u003cli\u003eFor research use only (RUO)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhy Researchers Choose It\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eRecognized competitive CGRP receptor antagonist with decades of literature support\u003c\/li\u003e\n\u003cli\u003eEssential tool for dissecting CGRP signaling pathways in pain and migraine research\u003c\/li\u003e\n\u003cli\u003eEnables validation of therapeutic CGRP blockade mechanisms\u003c\/li\u003e\n\u003cli\u003eRat sequence facilitates use in rodent pain models and in vitro systems\u003c\/li\u003e\n\u003cli\u003eHigh purity and convenient lyophilized storage format\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eFrequently Asked Questions (FAQ)\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHow does CGRP (8-37) differ from full-length CGRP?\u003c\/strong\u003e\u003cbr\u003eFull-length CGRP (1-37) is an agonist that activates the CGRP receptor. CGRP (8-37), missing the critical N-terminal 1-7 residues, is a competitive antagonist that blocks receptor binding.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIs CGRP (8-37) selective for the CGRP receptor?\u003c\/strong\u003e\u003cbr\u003eYes, it is selective for the calcitonin-gene-related peptide receptor. However, request the COA for any lot-specific selectivity data.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCan I use this peptide in vivo (in animals)?\u003c\/strong\u003e\u003cbr\u003eThis product is for research use only (RUO). In vivo efficacy and safety depend on route, dose, and formulation. Consult the literature and request guidance before in vivo studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShould I use rat CGRP (8-37) in rat studies?\u003c\/strong\u003e\u003cbr\u003eYes. Rat-derived peptide is ideal for rat models to minimize species mismatch and immune responses.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHow should I store reconstituted peptide?\u003c\/strong\u003e\u003cbr\u003eStore at 2–8°C for short-term use (hours to days), or freeze at −20°C if longer storage is needed. Avoid repeated freeze–thaw cycles.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin-top:20px; font-weight:bold; color:#c8102e;\"\u003eThis product is for Research Use Only (RUO). It is not intended for diagnostic or therapeutic use in humans or animals.\u003c\/div\u003e\n\u003chr\u003e\n\u003ch4\u003eReferences\u003c\/h4\u003e\n\u003cul style=\"padding-left:0; margin:0; list-style:none;\"\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eRussell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. \u003cem\u003ePhysiol Rev.\u003c\/em\u003e 2014;94(4):1099-142.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/physrev.00034.2013\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eGoodman EC, Iversen LL. Calcitonin gene-related peptide: novel neuropeptide. \u003cem\u003eLife Sci.\u003c\/em\u003e 1986;38(24):2169-78.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1016\/0024-3205(86)90568-0\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eBrain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. \u003cem\u003ePhysiol Rev.\u003c\/em\u003e 2004;84(3):903-34.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/physrev.00037.2003\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eEdvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. \u003cem\u003eNat Rev Neurol.\u003c\/em\u003e 2018;14(6):338-350.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1038\/s41582-018-0003-1\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eGoadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. \u003cem\u003ePhysiol Rev.\u003c\/em\u003e 2017;97(2):553-622.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1152\/physrev.00034.2015\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e","brand":"Molecular Depot","offers":[{"title":"Default Title","offer_id":52809017426218,"sku":"BTS-B2026702","price":585.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/B2026702.png?v=1790859410","url":"https:\/\/bluetigerscientific.com\/products\/calcitonin-gene-related-peptide-cgrp-8-37-rat","provider":"Blue Tiger Scientific","version":"1.0","type":"link"}